Tamper-sealed rubber stopper and aluminum cap
Main human AOD-9604 treatment timelines Study METAOD004 Participants 36 Route Oral Treatment length 7 days Dose range 9, 27, or 54 mg/day Main lesson Short safety and tolerability study Study METAOD005 Participants 300 Route Oral Treatment length 12 weeks Dose range 1 to 30 mg/day Main lesson Earlier weight-loss trial with a non-linear dose response Study METAOD006 Participants 502 randomized Route Oral Treatment length 24 weeks Dose range 0.25, 0.5, or 1 mg/day Main lesson Primary weight-loss goal was not met The oral milligram doses in these trials cannot be converted into subcutaneous microgram doses
GHK-Cu supports this phase through stimulation of angiogenesis and regulation of growth factor expression, ensuring adequate vascular supply and signaling for sustained cellular activity
While caloric deficit creates the energy imbalance necessary for fat loss, it does not specifically target resistant fat deposits or enhance receptor-mediated lipolysis
#3 Peptide Quality Control Risk: Avoid research chemical websites, which may sell impure contaminated incorrectly dosed products Only use peptides from trusted, FDA-regulated compounding pharmacies (503A/503B)
Many patients begin with a secure telehealth consultation before starting a provider-guided wellness plan